



Pharmaceuticals – Pipeline Overview¹ (as of May 02, 2025)

Phase I
Sevabertinib (HER2/mEGFR Inhibitor) (BAY 2927088)  ●
DGKzeta Inhibitor (BAY 2965501)  ●
Lanerkitug (CCR8 Ab) (BAY 3375968)  ●
VVD KEAP1 Act (VVD-130037 aka NRF2 Inh, BAY 3605349)  ●
DGKalpha Inh (BAY 2862789)  ●
225Ac-Pelgifatamab (BAY 3546828)  ●
VVD STAT3 Inhibitor (VVD-130850, BAY 3630914)  ●
225Ac-PSMA-Trillium (BAY 3563254)  ●
SOS1 Inhibitor (BAY 3498264)  ●
PRMT5 Inhibitor (BAY 3713372)  ●
VVD RAS-PI3K Inhibitor (VVD-159642, BAY 3674171)  ●
225Ac-GPC3 (BAY 3547926)  ●
SEMA 3a (BAY 3401016)  ●
Anti-coagulant (BAY 3389934)  ●
Atrial fibrillation ●
Bemdaneprocel (Parkinson's Disease Cell Therapy) (BRT-DA01)  ●
Multiple System Atrophy rAAV Gene Therapy (AB-1005 aka AAV2-GDNF-MSA)  ●
Pompe Disease rAAV Gene Therapy (ACTUS-101)  ●
LGMD2I/R9 rAAV Gene Therapy (AB-1003 aka LION-101)  ●
GPR84 Antagonist (BAY 3178275)  ●
BAY 2701250  ●

Phase II
Sevabertinib (HER2/mEGFR Inhibitor) (BAY 2927088)  ○ // Metastatic or Unresectable Solid Tumors With HER2-activating Mutations (panSOHO)
Congestive Heart Failure rAAV Gene Therapy (AB-1002)  ● // Congestive Heart Failure (GenePHIT)
Anti-a2AP (BAY 3018250)  ● // Acute Ischemic Stroke; Pulmonary Embolism (SIRIUS)
Nurandociguat (sGC Activator Oral) (BAY 3283142)  ● // Chronic Kidney Disease (ALPINE-1)
Parkinson's Disease rAAV Gene Therapy (AB-1005)  ● // Parkinson's Disease (REGENERATE-PD)

Phase III
Darolutamide (AR Inhibitor)  ○ // Adjuvant Prostate Cancer (DASL-HiCaP) // Prostate Cancer with Biochemical Recurrence after Curative Radiotherapy (ARASTEP)
Sevabertinib (HER2/mEGFR Inhibitor)  ● // Advanced Non-small Cell Lung Cancer with HER2 Activating Mutations, 1L (SOHO-02)
Finerenone (MR Antagonist)  ○ // Non-diabetic Chronic Kidney Disease (FIND-CKD) // Chronic Kidney Disease in Type 1 Diabetes (FINE-ONE)
Vericiguat (sGC Stimulator)  ○ // Heart Failure (HFrEF) (VICTOR ²)
Asundexian (FXIa Inhibitor)  ● // 2 ^o Stroke Prevention (OCEANIC-STROKE)
Gadoquatrane (High Relaxivity Contrast Agent)  ● // Magnetic Resonance Imaging (QUANTI-CNS, QUANTI-OB ²)

Submissions
Darolutamide (AR Inhibitor)  ○ // US, EU, CN: Prostate Cancer (mHSPC)
Finerenone (MR Antagonist)  ○ // US, EU, CN, JP: Heart Failure (HFmr/pEF)
Elinzanetant (Neurokinin-1,3 Rec Antagonist)  ● // US, EU: Vasomotor Symptoms
Aflibercept 8mg (VEGF-Inhibitor)  ○ // CN: Neovasc. Age-rel. Macular Degen. (nAMD) // EU: Retinal Vein Occlusion

	Oncology
	Cardiovascular+ ³
	Neurology & Rare Diseases
	Immunology
	Others
	New molecular entity
	Life cycle management

 Protein Therapeutics  Cell Therapy  Contrast Agent  Genetic Medicine  Radionuclide Therapy  Small Molecule

¹ Bayer and partner sponsored + 3rd party label enabling studies with first patient first visit
² Conducted by Merck & Co ³ Including Precision Cardiovascular, Nephrology & Acute Care